RESTEM Initiates First-in-Human Trial of Umbilical Cell Therapy for Facioscapulohumeral Muscular Dystrophy
核心洞察
RESTEM (搜索) has dosed the first patient with Restem-L umbilical lining modified progenitor cells (搜索) in a Phase 1/2a trial for facioscapulohumeral muscular dystrophy (搜索) (FSHD (搜索)).
The double-blind, placebo-controlled crossover study will enroll 16 patients to evaluate safety and preliminary efficacy of the off-the-shelf cell therapy.
FSHD (搜索) affects approximately 1 in 8,000 people worldwide and currently has no approved therapies, representing a significant unmet medical need.
RESTEM (搜索), a clinical-stage biotechnology company developing next-generation cell therapies, has announced the first patient dosing in a Phase 1/2a study of Restem-L for facioscapulohumeral muscular dystrophy (搜索) (FSHD (搜索)). The milestone marks the first clinical evaluation of the company's umbilical lining modified progenitor cells (搜索) (UMPCs (搜索)) in this rare neuromuscular disorder that affects up to 1 million patients worldwide.
The study is funded by SOLVE FSHD (搜索), a venture philanthropic organization established by lululemon founder Chip Wilson, who has committed $100 million to accelerate FSHD (搜索) research with the goal of finding a cure by 2027.
Novel Cell Therapy Approach for Rare Muscle Disease
Restem-L represents an off-the-shelf cell therapy platform designed to modulate immune system responses. According to Eva Chin, Ph.D., Executive Director of SOLVE FSHD (搜索), the organization selected RESTEM (搜索)'s technology after reviewing numerous platforms, impressed by the UMPCs (搜索)' ability to modulate key inflammatory factors in related muscle inflammatory conditions.
"FSHD (搜索) is a rare neuromuscular disease characterized by immune cell infiltration and inflammation in skeletal muscles, ultimately leading to their degeneration, progressive weakness and loss of facial and upper body function and eventually impaired mobility," Chin explained.
FSHD (搜索) affects approximately 1 in 8,000 people worldwide and is one of the most common forms of muscular dystrophy (搜索). The genetic muscle disorder typically begins in adolescence or early adulthood, causing progressive muscle weakness primarily affecting the face, shoulder blades, and upper arms. Currently, no cure exists, and available treatments focus only on symptom management and quality of life enhancement.
Comprehensive Trial Design
The Phase 1/2a study (NCT07086521) is a double-blind, randomized, dose-repeating, placebo-controlled crossover trial led by John Day, M.D., Ph.D. at Stanford University. The study aims to enroll 16 patients who will be randomized 1:1 to receive either Restem-L or placebo for six months, then crossed over to receive the alternate treatment for an additional six months.
The trial features a 12-month treatment duration with follow-up assessments at 15 and 21 months. The primary endpoint focuses on safety evaluation, while secondary and exploratory outcomes include serum markers of immune and inflammatory response, patient and clinician reported functional outcomes, MRI assessments, and muscle biopsy biomarkers.
Expanding Therapeutic Applications
For RESTEM (搜索), this trial represents an expansion beyond the company's primary focus on autoimmune diseases. "This clinical trial allows us to explore Restem-L's potential beyond autoimmune diseases, and expand our reach to other inflammatory-driven serious conditions with high unmet medical needs such as FSHD (搜索) - a genetic neuromuscular disease with no approved therapies," said Andres Isaias, Chief Executive Officer of RESTEM.
The company's approach centers on reprogramming the immune system rather than solely managing symptoms, potentially addressing underlying disease mechanisms. RESTEM (搜索) is advancing two main therapeutic programs: Restem-L for autoimmune diseases and activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders.
Philanthropic Partnership Drives Innovation
The collaboration between RESTEM (搜索) and SOLVE FSHD (搜索) highlights the role of venture philanthropy in advancing treatments for rare diseases. SOLVE FSHD was established to catalyze innovation and accelerate research toward finding an FSHD (搜索) cure, with founder Chip Wilson's $100 million commitment supporting projects aligned with the organization's mission.
"The initiation of this trial inches us closer to bringing hope to the up to 1 million patients estimated to suffer from FSHD (搜索) worldwide," Chin noted, emphasizing the significance of this first-patient milestone in a condition where effective treatments remain elusive.